Therapix is a specialty pharmaceutical company focused on synthetic cannabinoid based therapies with attractive risk/return profiles that target large, high value, under served markets
Quote | Therapix Biosciences Ltd. (NASDAQ:TRPX)
Last: | $0.317 |
---|---|
Change Percent: | -48.9% |
Open: | $0.3626 |
Close: | $0.317 |
High: | $0.3999 |
Low: | $0.3011 |
Volume: | 6,962,700 |
Last Trade Date Time: | 07/01/2020 04:56:03 pm |
News | Therapix Biosciences Ltd. (NASDAQ:TRPX)
Cannabis sales are determined by number of dispensaries and the availability to them by proximity. California has no restrictions regarding the number of dispensaries such as Washington State. Growth in cannabis in California will eclipse the entire cannabis industry's current ret...
Cannabis companies are starting to turn a profit and print positive EPS. Here are the few that are earning a profit. Many companies are close to turning a positive EPS. The industry itself is expected to expand some 100% in the next couple of years, and with economies of scale, th...
Message Board Posts | Therapix Biosciences Ltd. (NASDAQ:TRPX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Therapix Biosciences Ltd. Company Name:
TRPX Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel , Aug. 21, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the replacement of its board of directors. The Comp...
TEL AVIV, Israel , July 9, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that its American Depositary Shares ("ADSs") will no...
TEL AVIV, Israel , July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Inju...